Skip to Main Content

Paper Details

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nat Commun
438
2014
AXL, BRAF, ERK, MITF, MITF-high and -low clones, MITF-low melanomas, Microphthalmia-associated transcription factor, NRAS, NRAS mutant, melanoma, melanomas, mutant BRAF, mutant BRAF and NRAS melanoma cell lines, patient, receptor tyrosine kinases, tyrosine, vemurafenib
Author NameAffiliation
Oscar KrijgsmanThe Netherlands Cancer Institute
Kristel KemperThe Netherlands Cancer Institute
Colin R GodingLudwig Institute for Cancer Research, University of Oxford
Ultan McDermottWellcome Trust Sanger Institute
Antoni RibasDavid Geffen School of Medicine at University of California, University of California, Los Angeles (university of california los angeles), USA [3] Jonsson Comprehensive Cancer Center (JCCC)
Antoni RibasDavid Geffen School of Medicine at University of California, University of California, Los Angeles (university of california los angeles), USA [3] Jonsson Comprehensive Cancer Center (JCCC)
Daniel S PeeperThe Netherlands Cancer Institute
  • 1 - 7

Datasets

Release 1.2